Health Care & Life Sciences » Pharmaceuticals | CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
59.05 M
Public Float
38.72 M
CymaBay Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.34
Market Cap
$483.62 M
Shares Outstanding
68.7 M
Public Float
59.28 M

Profile

Address
7575 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.cymabay.com
Updated 07/08/2019
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Financials

View All
Created with Highcharts 5.0.14CymaBay Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.243 994243 99431 91731 91715 52915 52926 67126 67127 55727 55772 54872 548201320142015201620172018050k100k150k200k250k300k
Created with Highcharts 5.0.14CymaBay Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.0000000010 00010 00010510520132014201520162017201802.5k5k7.5k10k12.5k

Sujal Shah
President, Chief Executive Officer & Director
Robert James Wills
Chairman